Abstract: Glass cores including protruding through glass vias and related methods are disclosed herein. An example substrate disclosed herein includes a glass core including a surface and a copper through glass via (TGV) extending through the glass core, the TGV including a protrusion extending from the surface.

Abstract: Broadly speaking, embodiments of the present techniques provide haptic button assemblies in which the haptic button has a low profile while still providing a satisfying tactile response or sensation to a user. Advantageously, the haptic button assemblies may have a profile that, for example, enables the assembly to be incorporated into the free space along an edge of a portable computing device. The haptic assemblies may, for example, be arranged to move the button perpendicularly with respect to the edge of the device.

Abstract: This application relates to methods for overcoming or preventing resistance of a KRAS mutant cancer cell to a growth inhibition and/or cell death induction by a KRAS inhibitor or a SHP2 inhibitor, as well as to methods for enhancing sensitivity of a KRAS mutant cancer cell to a KRAS inhibitor or a SHP2 inhibitor. The application further relates to methods of treating a KRAS mutant cancer in a subject, the method comprising administering to the subject an effective amount of a KRAS inhibitor or a SHP2 inhibitor and an inhibitor of expression or function or a degrader or a binding partner of one or more of various proteins described herein. Related pharmaceutical compositions and kits are also disclosed.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

Abstract: The present disclosures are directed to personal care compositions comprising crosslinked silicone elastomer; personal care compositions comprising a crosslinked silicone elastomer powder that is free of surfactant; and personal care compositions that are free of a polyether compound. The present disclosures are further directed to personal care compositions comprising one or more of oils, an aqueous phase, sunscreens, film formers, waxes, emulsifiers, particulates, pigments, dyes, and preservatives.

Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition or IL-11-mediated signalling.

Abstract: The invention relates to a method for providing at least one piece of information about a hydraulic apparatus (1), wherein the following stages are performed: Performing a detection (201) of detection values (210) at the apparatus (1), wherein the detection values (210) are specific for measurements at different measuring points and at different apparatus components (120) of the apparatus (1), Performing a transmission (202) of the detected detection values (210) to a processing component (300), Providing an apparatus information (211) about a specification of the apparatus (1) and/or the measurements, wherein providing the apparatus information (211) is performed at the processing component (300) to provide the transmitted detection values (210) with the apparatus information (211).

Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.

Abstract: An electric motor, in particular a separately excited synchronous motor, has a rotor shaft with at least one slip ring and at least one electrically conductive contact element, in particular a carbon brush, which bears against the slip ring and is accommodated in a channel-like guide formed in a housing and extending radially with respect to the rotor shaft and which carbon brush is radially tensioned against the slip ring by means of a spring element, wherein a roller is provided which is tensioned laterally against the contact element via a further spring element and via which the contact element is tensioned against a wall of the guide.

Abstract: An electric motor, in particular a separately excited synchronous motor, comprises a rotor shaft with at least one slip ring and at least one electrically conductive contact element, in particular a carbon brush, which bears against the slip ring and is accommodated in a channel-like guide formed in a housing and extending radially with respect to the rotor shaft and which carbon brush is radially tensioned against the slip ring by means of a spring element, wherein a roller is provided which is tensioned laterally against the contact element via a further spring element and via which the contact element is tensioned against a wall of the guide.

Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.